Merck Q3: Zostavax Nears Part D Hurdles, Gardasil Sales On Fast Track

Merck will seek to drive continued growth of its shingles vaccine Zostavax through promotional activity and efforts to facilitate reimbursement, the firm said

More from Archive

More from Pink Sheet